BLA 761225 · Hugel INC
Letybo
Letibotulinumtoxina-Wlbg · Acetylcholine Release Inhibitor; Neuromuscular Blocker
NovelCDER novel approval, Feb 29, 2024: To temporarily improve the appearance of moderate-to-severe glabellar lines
Last checked: Nov 20, 2026Latest source record: Feb 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Feb 29, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
293
30 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including LETYBO, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. LETYBO is not approved for the treatment of spasticity or any conditions other than glabellar lines [see Warnings and Precautions ( 5.1 )] . WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of all botulinum toxin products, including LETYBO, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening...
What it is approved for
From the label in effect Nov 18, 2024.
LETYBO is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. LETYBO is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. ( 1 )
Mechanism: LETYBO blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine. When injected intramuscularly at therapeutic doses, LETYBO is internalized into the nerve terminal, translocates into the neuronal cytosol where it cleaves SNAP25, a protein necessary for synaptic membrane docking and subsequent release of acetylcholine which produces a dose dependent decrease of muscle function. Recovery of muscle function is gradual due to degradation of the neurotoxin and formation of axonal sprouts. Muscle reinnervation occurs, leading to a slow reversal of the...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 29, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelMedication GuideLetter
1 products under this application
- LETYBO · LETIBOTULINUMTOXINA-WLBG 0.1ML(4UNITS) · POWDER, FOR SOLUTION, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Letibotulinumtoxina" as an intervention, any sponsor and status, largest first.
- Outcome of Treatment With Botulinum toxinA in Patients With Temporomandibular Myofascial PainPivotal-lookingCompleted
PAEC General Hospital, IslamabadAcademic, hospital or other
NCT07668375 · 118 participants · Start Jan 2, 2026 · Primary completion Apr 1, 2026
Drug: Botulinum Toxin-A (Botulax - letibotulinumtoxinA); Normal Saline · For: Myofascial Pain - Dysfunction Syndrome of TMJ
Sites: Islamabad, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- therapy non-responder143
- drug effect less than expected81
- botulism15
- drug ineffective15
- headache11
- off label use10
- product quality issue10
- dysphagia9
- dyspnoea8
- injection site pain8
- chest discomfort7
- eyelid ptosis6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 6 |
| 2025 | 138 |
| 2026 | 149 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical Trials.
Cox SE, Kaufman-Janette J, Cohen JL, et al. · Dermatol Surg 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of LetibotulinumtoxinA Injection for Trapezius Hypertrophy: A Prospective, Randomized, Double-Blind Trial.
Kim TH, Kang HI, Lee SJ, et al. · Aesthetic Plast Surg 2026 · Randomized Controlled Trial
- Efficacy and Safety of LetibotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Systematic Review and Meta-Analysis of RCTs.
Masood M, Khan RSS, Masood S, et al. · Aesthetic Plast Surg 2026 · Systematic Review, Meta-Analysis
- Safety and efficacy of letibotulinumtoxinA(BOTULAX®) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial.
Do KH, Chun MH, Paik NJ, et al. · Clin Rehabil 2017 · Clinical Trial, Phase III, Multicenter Study
- Time course response after single injection of botulinum toxin to treat spasticity after stroke: Systematic review with pharmacodynamic model-based meta-analysis.
Ojardias E, Ollier E, Lafaie L, et al. · Ann Phys Rehabil Med 2022 · Meta-Analysis, Systematic Review
Sponsor: Hugel INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.